Resonance Health Ltd. provides the following update that In demonstrating that AS3 is highly efficacious in a humanised-liver mouse model, the Company has achieved a significant milestone. On that basis, the Company has commenced discussions with an experienced academic team to develop a collaborative study with the objective of evaluating AS3 in a humanised-liver mouse model of Hepatitis B virus infection. The company hope to commence this work late 2021 or early 2022 for completion in the first half of 2022.